Nausea and Vomiting Rates in Tigecycline Clinical Trials
Tigecycline, an antibiotic used for complicated infections, commonly causes gastrointestinal side effects. In pivotal phase 3 trials, nausea occurred in 26-30% of patients overall, with vomiting in 18-20%. These rates were higher than comparators like vancomycin or imipenem (nausea 14-15%, vomiting 8-11%). Most events were mild to moderate and happened early, often on day 1.[1][2]
How Rates Differ by Indication and Dose
- Skin/skin structure infections: Nausea 23%, vomiting 15%.
- Intra-abdominal infections: Nausea 27%, vomiting 19%.
- Pneumonia: Nausea 29%, vomiting 20%.
Intravenous doses of 100 mg loading followed by 50 mg every 12 hours drove these rates; oral formulations aren't available. Discontinuation due to nausea was 2-4%, vomiting 1-2%.[1][2]
Factors Raising Nausea/Vomiting Risk
Higher incidence in females (32% nausea vs. 25% males) and elderly patients. Rates doubled in ventilator-associated pneumonia trials (nausea ~40%). Infusion over 30-60 minutes and antiemetics like ondansetron reduce severity.[1][3]
Management and Patient Experiences
Guidelines recommend premedication with antiemetics and slower infusions. Patients report symptoms peak within 24-48 hours and resolve post-treatment, but 5-10% experience severe cases needing intervention. No long-term GI risks noted.[2][3]
Comparison to Other Antibiotics
Tigecycline's GI effects exceed carbapenems (nausea <15%) and linezolid (10-15%), but it's similar to some tetracyclines. This profile limits outpatient use.[1]
[1]: Tigecycline Prescribing Information (FDA)
[2]: ClinicalTrials.gov summaries for TYGACIL trials (NCT00079217, NCT00091819)
[3]: DrugPatentWatch.com - Tigecycline side effect profile